Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Locally Advanced HNSCC
NCT05433116Phase 2Active, not recruiting
- Sponsor
- Saarland University
- Start
- May 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Saarland University. Started May 2023; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05433116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433116.